{"title":"Hepatitis Viruses","description":null,"products":[{"product_id":"hba-020","title":"Hepatitis B virus core antigen (RECOMBINANT)","description":"\u003cp\u003eThe HBcAg is produced by genetically engineered E. coli cells and purified by column chromatography and CsCl density gradient sedimentation.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e The antigen is formulated at 0.75 mg\/mL in 100mM NaCO3 (pH 9.3)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. The hepatitis B virus. P. Tiollais et al. Nature 317, 489 (1985).\u003cbr\u003e2. Hepatitis B virus core antigen: Synthesis in E. coli and applications in diagnostics. S. Stahl et al. Proc. Natl. Acad. Sciences USA 79, 1606 (1981).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HBA-020_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518875234606,"sku":"HBA-020-4","price":155.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518875267374,"sku":"HBA-020-5","price":425.0,"currency_code":"USD","in_stock":true},{"title":"250 µg","offer_id":52518875300142,"sku":"HBA-020-7","price":595.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hba-020-50ug.png?v=1788008796"},{"product_id":"hba-010","title":"Hepatitis B virus surface antigen (RECOMBINANT)","description":"\u003cp\u003eThe HBsAg is produced by genetically engineered CHO cells and purified by column chromatography and CsCl density sedimentation. The antigen contains the preS2 region.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution 1.0 mg\/mL in 10mM Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. The hepatitis B virus. P. Tiollais et al., Nature 317, 489 (1985).\u003cbr\u003e2. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized BSA. Mitchell et al. Proc. Natl. Acad. Sci. USA 81, 7708 (1984).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HBA-010_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518875136302,"sku":"HBA-010-4","price":155.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518875169070,"sku":"HBA-010-5","price":425.0,"currency_code":"USD","in_stock":true},{"title":"250 µg","offer_id":52518875201838,"sku":"HBA-010-7","price":595.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hba-010-50ug.png?v=1788008627"},{"product_id":"hbm-011","title":"Anti-Hepatitis B virus surface antigen IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-hepatitis B surface antigen IgG fraction is a mouse monoclonal antibody to HBsAg (Clone 4B9). It has been purified by affinity chromatography) using Protein G. It is not recomended for Western blot analysis.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody will recognize the antigen on a dot blot under non-denaturated conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.45 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HBM-011_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875332910,"sku":"HBM-011-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hbm-011-100ug.png?v=1788008588"},{"product_id":"hbm-021","title":"Anti-Hepatitis B virus core antigen IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-hepatitis B core antigen IgG fraction is a mouse monoclonal antibody (Clone 2C11\/2) to native HBcAg particles. The antigen used for immunization is highly purified HBcAg produced by recombinant E. coli cells. It has been purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The antibody is reactive in ELISA and also immunoprecipitation of native hepatitis B core particles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HBM-021_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875365678,"sku":"HBM-021-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hbm-021-100ug.png?v=1788008601"},{"product_id":"hbp-014","title":"Goat anti-Hepatitis B virus surface antigen IgG fraction (polyclonal)","description":"\u003cp\u003eAnti-hepatitis B surface antigen IgG fraction is a polyclonal antibody raised in goats against highly purified HBsAg made in CHO cells.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody may be used for Western blot analysis (1:100\/1:1000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution 1.0 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HBP-014_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"1mg","offer_id":52517542396206,"sku":"HBP-014-9","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hbp-014-1mg.png?v=1788008628"},{"product_id":"hbp-023","title":"Anti-Hepatitis B Virus Core Antigen, IgG Fraction, Polyclonal","description":"\u003cp\u003eAnti-hepatitis B-core IgG fraction is a polyclonal antibody raised in rabbit against purified recombinant hepatitis B-core . It is purified using Protein G.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This polyclonal antibody recognizes recombinant hepatitis B-core by Western analysis and ELISA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 1.0 mg\/mL. Formulated in 0.1 M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hbp-023\"\u003ePublications using Austral Biologicals HBP-023-9\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of Austral Biologicals HBP-023-9:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.2603476123\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis B virus covalently closed circular DNA formation in murine hepatic cells uncovers a late entry block\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHong et al., Proc Natl Acad Sci U S A 123(17):e2603476123 (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/v18020187\" rel=\"noopener\" target=\"_blank\"\u003eDevelopment of a Novel Human Hepatoma Cell Line Supporting the Replication of a Recombinant HBV Genome with a Reporter Gene\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKawase et al., Viruses 18(2):187 (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1013776\" rel=\"noopener\" target=\"_blank\"\u003eNetrin-1 inhibits the attachment and internalization of Hepatitis B virus for hepatocyte infection\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., PLoS Pathog 21(12):e1013776 (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/s12072-025-10776-9\" rel=\"noopener\" target=\"_blank\"\u003eGut microbes associated with functional cure of chronic hepatitis B\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHonda et al., Hepatol Int 19(3):519-528 (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.antiviral.2024.105821\" rel=\"noopener\" target=\"_blank\"\u003eAntiviral effect of peptoids on hepatitis B virus infection in cell culture\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMurayama et al., Antiviral Res 223:105821 (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1097\/hc9.0000000000000206\" rel=\"noopener\" target=\"_blank\"\u003eFunctional involvement of endothelial lipase in hepatitis B virus infection\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eShirasaki et al., Hepatol Commun 7(9):e0206 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.21769\/bioprotoc.4779\" rel=\"noopener\" target=\"_blank\"\u003eProduction and Purification of Cell Culture-generated Hepatitis B Virus by Transient Transfection and Density Gradient\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMurayama et al., Bio Protoc 13(14):e4779 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1126\/sciadv.adg6265\" rel=\"noopener\" target=\"_blank\"\u003eAn RNA-based system to study hepatitis B virus replication and evaluate antivirals\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYu et al., Sci Adv 9(15):eadg6265 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/mbio.03303-22\" rel=\"noopener\" target=\"_blank\"\u003eLive Cell Imaging Reveals HBV Capsid Translocation from the Nucleus To the Cytoplasm Enabled by Cell Division\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRomero et al., mBio 14(2):e0330322 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.virusres.2022.199014\" rel=\"noopener\" target=\"_blank\"\u003eIdentification of neutralizing epitopes in the preS2 domain of the hepatitis B virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYato et al., Virus Res 323:199014 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41467-022-32910-z\" rel=\"noopener\" target=\"_blank\"\u003eNeutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWashizaki et al., Nat Commun 13(1):5207 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00767-21\" rel=\"noopener\" target=\"_blank\"\u003eMafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIbrahim et al., J Virol 95(15):e0076721 (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.chom.2020.05.010\" rel=\"noopener\" target=\"_blank\"\u003eA Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Cell Host Microbe 28(2):335-349.e6 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.1919035117\" rel=\"noopener\" target=\"_blank\"\u003eExpansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMichailidis et al., Proc Natl Acad Sci U S A 117(3):1678-1688 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/v11070651\" rel=\"noopener\" target=\"_blank\"\u003eEffects of Moloney Leukemia Virus 10 Protein on Hepatitis B Virus Infection and Viral Replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePuray-Chavez et al., Viruses 11(7):E651 (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1021\/acsinfecdis.8b00235\" rel=\"noopener\" target=\"_blank\"\u003eNovel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuber et al., ACS Infect Dis 5(5):750-758 (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/mspheredirect.00131-18\" rel=\"noopener\" target=\"_blank\"\u003eThe Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuber et al., mSphere 3(2):e00131-18 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-017-16882-5\" rel=\"noopener\" target=\"_blank\"\u003eA robust cell culture system supporting the complete life cycle of hepatitis B virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMichailidis et al., Sci Rep 7(1):16616 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01229-16\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis B Virus Polymerase Localizes to the Mitochondria, and Its Terminal Protein Domain Contains the Mitochondrial Targeting Signal\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eUnchwaniwala et al., J Virol 90(19):8705-8719 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.03014-12\" rel=\"noopener\" target=\"_blank\"\u003eGenetically altering the thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus replication in cell culture\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTan et al., J Virol 87(6):3208-3216 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HBP-023_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"1mg","offer_id":52517542428974,"sku":"HBP-023-9","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hbp-023-1mg.png?v=1788008629"},{"product_id":"hca-070","title":"Hepatitis C Virus Core Antigen, Recombinant","description":"\u003cp\u003eRecombinant HCV (subtype 1a) protein made in yeast cells. Covers from methionine 1 to glycine 120 of the HCV polyprotein. It is a fusion protein with human superoxide dismutase (SOD).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 36 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA with serum from HCV positive individuals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.75 mg\/mL in sodium borate, 10mM thiocyanate, 10mM DTT, 5mM EDTA, (pH 9.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. The genetic organization and diversity of hepatitis C virus. Q-L. Choo et al., Proc. Natl. Acad. Sci. USA 88, 2451 (1991).\u003cbr\u003e2. Hepatitis C viruses. Michael Houghton, In Fields Virology, Third Edition (Fields, B.N; Knipe, D.M. and Howley, P.M. Editors), Raven Publishers, page 1035 (1996)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hca-070\"\u003ePublications using HCA-070\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/s00425-026-04956-6\" rel=\"noopener\" target=\"_blank\"\u003ePlant-based production of virus-like particles from hepatitis C virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLópez-Castillo et al., Planta 263(4):86 (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0154433\" rel=\"noopener\" target=\"_blank\"\u003eHCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV\/HCV Coinfection\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMacParland et al., PLoS One 11(4):e0154433 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCA-070_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518875398446,"sku":"HCA-070-3","price":125.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518875431214,"sku":"HCA-070-4","price":455.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hca-070-10ug.png?v=1788008611"},{"product_id":"hca-090","title":"Hepatitis C Virus E2 Antigen, Recombinant","description":"\u003cp\u003eRecombinant HCV (subtype 1a) protein made in CHO cells. Covers from Glu 383 to Ala 745 of the HCV-1a polyprotein.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 55 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e It has a MW of 55,000, however it runs anomalously on PAGE.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.20 mg\/mL in 10mM sodium phosphate, 0.1M NaCI, (pH 6.2)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. The Genetic Organization and Diversity of Hepatitis C virus. Q-L. Choo et al., Proc. Natl. Acad. Sci. USA 88, 2451 (1991).\u003cbr\u003e2. Hepatitis C viruses. Michael Houghton, In Fields Virology, Third Edition (Fields, B.N; Knipe, D.M. and Howley, P.M. Editors), Raven Publishers, page 1035 (1996)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hca-090\"\u003ePublications using HCA-090\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/s00425-026-04956-6\" rel=\"noopener\" target=\"_blank\"\u003ePlant-based production of virus-like particles from hepatitis C virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLópez-Castillo et al., Planta 263(4):86 (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.jasms.2007.11.022\" rel=\"noopener\" target=\"_blank\"\u003eMass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIacob et al., J Am Soc Mass Spectrom 19(3):428-444 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01206-06\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMcLinden et al., J Virol 80(24):12131-12140 (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCA-090_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518875463982,"sku":"HCA-090-2","price":395.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hca-090-5ug.png?v=1788008607"},{"product_id":"hca-100","title":"Hepatitis C virus NS3\/NS4 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein is derived from HCV-1a, and made in yeast cells as a fusion with human superoxide dismutase (SOD). It covers Asp 1569 to Pro 1931 of the HCV polyprotein. It is equivalent to the C-100 antigen.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 53 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA with serum from HCV positive individuals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 20mM Tris-HCl, 0.1% SDS 10mM DTT (pH 7.0)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. The genetic organization and diversity of hepatitis C virus. Q-L. Choo et al., Proc. Natl. Acad. Sci. USA 88, 2451 (1991).\u003cbr\u003e2. Hepatitis C viruses. Michael Houghton, In Fields Virology, Third Edition (Fields, B.N; Knipe, D.M. and Howley, P.M. Editors), Raven Publishers, page 1035 (1996)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCA-100_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518875496750,"sku":"HCA-100-3","price":95.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518875529518,"sku":"HCA-100-4","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hca-100-10ug.png?v=1788008588"},{"product_id":"hca-110","title":"Hepatitis C virus NS3 antigen (RECOMBINANT)","description":"\u003cp\u003eMaterial is derived from HCV-1a, and produced in E. coli as a fusion protein with human superoxide dismutase (SOD). It covers Ala 1192 to Cys 1457 of the HCV polyprotein. It is equivalent to the c33c antigen.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 45 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in 50mM Tris-HCl, 50mM NaCl, 10mM DTT, 1mM EDTA (pH 7.4)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. The genetic organization and diversity of hepatitis C virus. Q-L. Choo et al., Proc. Natl. Acad. Sci. USA 88, 2451 (1991).\u003cbr\u003e2. Hepatitis C viruses. Michael Houghton In Fields Virology, Third Edition (Fields, B.N; Knipe, D.M. and Howley, P.M. Editors), Raven Publishers, page 1035 (1996)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCA-110_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518875562286,"sku":"HCA-110-3","price":95.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518875595054,"sku":"HCA-110-4","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hca-110-10ug.png?v=1788008612"},{"product_id":"hca-120","title":"Hepatitis C virus NS4 antigen (RECOMBINANT)","description":"\u003cp\u003eAntigen is produced in E. coli as a fusion with human superoxide dismutase (SOD). It covers from Ile 1694 to Leu 1735 of the HCV-1a polyprotein. It is equivalent to the 5-1-1 antigen.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 29 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This protein reacts in ELISA and dot blots with serum from HCV seropositive individuals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in 50mM sodium borate, 0.5M NaCl, 20mM DTT, 2mM EDTA (pH 8.4)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. The genetic organization and diversity of hepatitis C virus. Q-L. Choo et al., Proc. Natl. Acad. Sci. USA 88, 2451 (1991).\u003cbr\u003e2. Hepatitis C viruses. Michael Houghton In Fields Virology, Third Edition (Fields, B.N; Knipe, D.M. and Howley, P.M. Editors), Raven Publishers, page 1035 (1996)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCA-120_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518875627822,"sku":"HCA-120-3","price":95.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518875660590,"sku":"HCA-120-4","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hca-120-10ug.png?v=1788008627"},{"product_id":"hca-130","title":"Hepatitis C virus NS5 antigen (RECOMBINANT)","description":"\u003cp\u003eMade in yeast as a fusion protein with human superoxide dismutase (SOD). It covers Asn 2054 to Cys 2995 of the HCV polyprotein.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 150 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This protein reacts in ELISA with serum of HCV seropositive individuals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.8 mg\/mL in 20mM MES, 100mM NaCl, 10mM DTT, 1mM EDTA and 0.1% SDS (pH 6.0)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. The genetic organization and diversity of hepatitis C virus. 1. Q-L. Choo et al., Proc. Natl. Acad. Sci. USA 88, 2451 (1991).\u003cbr\u003e2. Hepatitis C viruses. Michael Houghton In Fields Virology, Third Edition (Fields, B.N; Knipe, D.M. and Howley, P.M. Editors), Raven Publishers, page 1035 (1996)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCA-130_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518875693358,"sku":"HCA-130-3","price":95.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518875726126,"sku":"HCA-130-4","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hca-130-10ug.png?v=1788008627"},{"product_id":"hcm-071","title":"Anti-Hepatitis C Virus Core Antigen, IgG Fraction, Monoclonal","description":"\u003cp\u003eMouse monoclonal antibody which recognizes the epitope located between Lys 10 and Ser 53 of the HCV (subtype 1a) polyprotein. Obtained by immunization with highly purified hepatitis C core antigen (Clone 4H2-2).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA as well as in dot blot tests. IgG Subtype: IgG-1.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in PBS (pH 7.4)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hcm-071\"\u003ePublications using HCM-071\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/cvi.00468-09\" rel=\"noopener\" target=\"_blank\"\u003eConstruction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSominskaya et al., Clin Vaccine Immunol 17(6):1027-1033 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.02043-09\" rel=\"noopener\" target=\"_blank\"\u003eGenetic analysis of the carboxy-terminal region of the hepatitis C virus core protein\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKopp et al., J Virol 84(4):1666-1673 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1086\/524846\" rel=\"noopener\" target=\"_blank\"\u003eSpecific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJhaveri et al., J Infect Dis 197(2):283-291 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00793-07\" rel=\"noopener\" target=\"_blank\"\u003eAlanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMurray et al., J Virol 81(19):10220-10231 (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1136\/gut.2005.070417\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSato et al., Gut 55(12):1801-1808 (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-071_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875758894,"sku":"HCM-071-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-071-100ug.png?v=1788008477"},{"product_id":"hcm-081","title":"Anti-Hepatitis C Virus E1 Antigen, IgG Fraction, Monoclonal","description":"\u003cp\u003eMouse monoclonal antibody recognizing a linear epitope of HCVE1 clone 4E6\/D4.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used for ELISA, for immunoprecipitation, and for immunofluorescence. IgG Subtype: Isotype IgG-1.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hcm-081\"\u003ePublications using HCM-081\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.02484-09\" rel=\"noopener\" target=\"_blank\"\u003eSuppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eShao et al., J Virol 84(12):6060-6069 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.77.24.13418-13424.2003\" rel=\"noopener\" target=\"_blank\"\u003eExpression of unmodified hepatitis C virus envelope glycoprotein-coding sequences leads to cryptic intron excision and cell surface expression of E1\/E2 heterodimers comprising full-length and partially deleted E1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDumonceaux et al., J Virol 77(24):13418-13424 (2003).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-081_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875791662,"sku":"HCM-081-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-081-100ug.png?v=1788008612"},{"product_id":"hcm-091a","title":"Anti-Hepatitis C Virus E2 Antigen, IgG Fraction, Monoclonal, Epitope a","description":"\u003cp\u003eMouse monoclonal antibody recognizing a linear epitope of HCV E2 (Clone 4F6\/2). It has been produced using highly purified HCV E2 glycoprotein.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This product can be used for ELISA and Western blot analysis, immunoprecipitation and immunofluorescence. Reacts in ELISA with serum from HCV seropositive individuals. IgG Subtype: IgG-1.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS (pH 7.4)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hcm-091a\"\u003ePublications using HCM-091A\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of the HCM-091A-5 antibody:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01053-16\" rel=\"noopener\" target=\"_blank\"\u003eThe Intracellular Cholesterol Transport Inhibitor U18666A Inhibits the Exosome-Dependent Release of Mature Hepatitis C Virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eElgner et al., J Virol 90(24):11181-11196 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.02043-09\" rel=\"noopener\" target=\"_blank\"\u003eGenetic analysis of the carboxy-terminal region of the hepatitis C virus core protein\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKopp et al., J Virol 84(4):1666-1673 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-091A_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875824430,"sku":"HCM-091a-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-091a-100ug.png?v=1788008588"},{"product_id":"hcm-091b","title":"Anti-Hepatitis C virus E2 antigen IgG fraction (Monoclonal epitope b)","description":"\u003cp\u003eMouse monoclonal antibody recognizing a conformational epitope of HCV-E2 (Clone 6F6\/I8). It has been produced highly purified HCV-E2 glycoprotein.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e It can be used for ELISA and for affinity purification of HCV-E2. IgG Subtype: IgG-1.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in PBS (pH 7.2)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-091B_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875857198,"sku":"HCM-091b-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-091b-100ug.png?v=1788008587"},{"product_id":"hcm-101","title":"Anti-Hepatitis C virus NS3\/NS4 antigen (C-terminal region) IgG fraction (monoclonal)","description":"\u003cp\u003eMouse monoclonal antibody recognizing the C-terminal region of the C-100 antigen covering aa1920 to aa1935 of the HCV (subtype 1a) polyprotein. (Clone 7B2\/I11).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and in dot blots. Also reacts in Western blots at 1:100 dilution, detecting 50 ng of the antigen. IgG Subtype: IgG-1.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-101_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875889966,"sku":"HCM-101-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-101-100ug.png?v=1788008518"},{"product_id":"hcm-111","title":"Anti-Hepatitis C virus NS3 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eMouse monoclonal antibody reacting with the HCV NS3 (subtype 1a) antigen (Clone 5E2\/2)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody reacts in ELISA and dot blots.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in Tris-HC1 (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-111_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875922734,"sku":"HCM-111-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-111-100ug.png?v=1788008496"},{"product_id":"hcm-121","title":"Anti-Hepatitis C virus NS4 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eMouse monoclonal antibody recognizing the epitope covering aa 1694 to aa 1735 of the HCV (subtype 1a) polyprotein (Clone 4E12\/I8).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody reacts in ELISA and in dot blots.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-121_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875955502,"sku":"HCM-121-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-121-100ug.png?v=1788008611"},{"product_id":"hcm-131","title":"Anti-Hepatitis C Virus NS5 Antigen, IgG Fraction, Monoclonal","description":"\u003cp\u003eMouse monoclonal antibody recognizing the NS5 antigen (Clone 2F6\/G11) spanning N2054-C2295 of the HCV (subtype 1a) sequence. It has been produced using highly purified NS-5 antigen.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody is reactive in ELISA and dot blot tests. IgG Subtype: IgG-1.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hcm-131\"\u003ePublications using Austral Biologicals HCM-131-5\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of Austral Biologicals HCM-131-5:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.jbc.2024.107286\" rel=\"noopener\" target=\"_blank\"\u003eProximity labeling of host factor ANXA3 in HCV infection reveals a novel LARP1 function in viral entry\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBley et al., J Biol Chem 300(5):107286 (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1009496\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis C virus infection restricts human LINE-1 retrotransposition in hepatoma cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSchöbel et al., PLoS Pathog 17(4):e1009496 (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.02009-18\" rel=\"noopener\" target=\"_blank\"\u003eDehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSahuc et al., J Virol 93(10):e02009-18 (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01997-17\" rel=\"noopener\" target=\"_blank\"\u003eRoles of the 5' Untranslated Region of Nonprimate Hepacivirus in Translation Initiation and Viral Replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTanaka et al., J Virol 92(7):e01997-17 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00355-17\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis C Virus Subverts Human Choline Kinase-α To Bridge Phosphatidylinositol-4-Kinase IIIα (PI4KIIIα) and NS5A and Upregulates PI4KIIIα Activation, Thereby Promoting the Translocation of the Ternary Complex to the Endoplasmic Reticulum for Viral Replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWong MT and Chen SS, J Virol 91(16):e00355-17 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1006374\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of miR-122-independent propagation of HCV\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOno et al., PLoS Pathog 13(5):e1006374 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/srep41452\" rel=\"noopener\" target=\"_blank\"\u003eRNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTsai et al., Sci Rep 7:41452 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.18632\/oncotarget.12144\" rel=\"noopener\" target=\"_blank\"\u003eSmall heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eConti et al., Oncotarget 7(51):84575-84586 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01615-16\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis C Virus Is Released via a Noncanonical Secretory Route\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBayer et al., J Virol 90(23):10558-10573 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00960-16\" rel=\"noopener\" target=\"_blank\"\u003eHuman Choline Kinase-α Promotes Hepatitis C Virus RNA Replication through Modulation of Membranous Viral Replication Complex Formation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWong MT and Chen SS, J Virol 90(20):9075-9095 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00404-16\" rel=\"noopener\" target=\"_blank\"\u003eIdentification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eVausselin et al., J Virol 90(19):8422-8434 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/ncomms12203\" rel=\"noopener\" target=\"_blank\"\u003eSeptin 9 induces lipid droplets growth by a phosphatidylinositol-5-phosphate and microtubule-dependent mechanism hijacked by HCV\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAkil et al., Nat Commun 7:12203 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0155708\" rel=\"noopener\" target=\"_blank\"\u003eHCV-Mediated Apoptosis of Hepatocytes in Culture and Viral Pathogenesis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSilberstein et al., PLoS One 11(6):e0155708 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0148711\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eStindt et al., PLoS One 11(2):e0148711 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0142539\" rel=\"noopener\" target=\"_blank\"\u003eClaudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFénéant et al., PLoS One 10(11):e0142539 (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01513-15\" rel=\"noopener\" target=\"_blank\"\u003eY-Box Binding Protein 1 Stabilizes Hepatitis C Virus NS5A via Phosphorylation-Mediated Interaction with NS5A To Regulate Viral Propagation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., J Virol 89(22):11584-11602 (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00192-15\" rel=\"noopener\" target=\"_blank\"\u003eNew Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFénéant et al., J Virol 89(16):8346-8364 (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/aac.03293-14\" rel=\"noopener\" target=\"_blank\"\u003eNS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eReghellin et al., Antimicrob Agents Chemother 58(12):7128-7140 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0102511\" rel=\"noopener\" target=\"_blank\"\u003eVisualization and analysis of hepatitis C virus structural proteins at lipid droplets by super-resolution microscopy\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eEggert et al., PLoS One 9(7):e102511 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0099022\" rel=\"noopener\" target=\"_blank\"\u003eNonstructural protein 5A is incorporated into hepatitis C virus low-density particle through interaction with core protein and microtubules during intracellular transport\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLai et al., PLoS One 9(6):e99022 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/mcp.m113.036301\" rel=\"noopener\" target=\"_blank\"\u003eThe intraviral protein interaction network of hepatitis C virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHagen et al., Mol Cell Proteomics 13(7):1676-1689 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0092343\" rel=\"noopener\" target=\"_blank\"\u003eLymphocytes as liver damage mirror of HCV related adipogenesis deregulation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMinutolo et al., PLoS One 9(3):e92343 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.03839-13\" rel=\"noopener\" target=\"_blank\"\u003eNovel permissive cell lines for complete propagation of hepatitis C virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eShiokawa et al., J Virol 88(10):5578-5594 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.03055-13\" rel=\"noopener\" target=\"_blank\"\u003eInnate immune response induced by baculovirus attenuates transgene expression in mammalian cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOno et al., J Virol 88(4):2157-2167 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1003775\" rel=\"noopener\" target=\"_blank\"\u003eSPOC1-mediated antiviral host cell response is antagonized early in human adenovirus type 5 infection\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSchreiner et al., PLoS Pathog 9(11):e1003775 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/hep.26273\" rel=\"noopener\" target=\"_blank\"\u003eThe antimalarial ferroquine is an inhibitor of hepatitis C virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eVausselin et al., Hepatology 58(1):86-97 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1003302\" rel=\"noopener\" target=\"_blank\"\u003eLipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eVogt et al., PLoS Pathog 9(4):e1003302 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.m112.434910\" rel=\"noopener\" target=\"_blank\"\u003eDiacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCamus et al., J Biol Chem 288(14):9915-9923 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1111\/cmi.12112\" rel=\"noopener\" target=\"_blank\"\u003eEWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePotel et al., Cell Microbiol 15(7):1234-1252 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00567-12\" rel=\"noopener\" target=\"_blank\"\u003eExpression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFukuhara et al., J Virol 86(15):7918-7933 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.06327-11\" rel=\"noopener\" target=\"_blank\"\u003eAnnexin A2 is involved in the formation of hepatitis C virus replication complex on the lipid raft\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSaxena et al., J Virol 86(8):4139-4150 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.06001-11\" rel=\"noopener\" target=\"_blank\"\u003eProline-serine-threonine phosphatase-interacting protein 2 (PSTPIP2), a host membrane-deforming protein, is critical for membranous web formation in hepatitis C virus replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChao et al., J Virol 86(3):1739-1749 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.06242-11\" rel=\"noopener\" target=\"_blank\"\u003eEstablishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKambara et al., J Virol 86(3):1382-1393 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.06099-11\" rel=\"noopener\" target=\"_blank\"\u003eDysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTaguwa et al., J Virol 85(24):13185-13194 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0022808\" rel=\"noopener\" target=\"_blank\"\u003eGeneration of a cell culture-adapted hepatitis C virus with longer half life at physiological temperature\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKim et al., PLoS One 6(8):e22808 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.m111.220103\" rel=\"noopener\" target=\"_blank\"\u003eInteracting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMontpellier et al., J Biol Chem 286(16):13954-13965 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0015967\" rel=\"noopener\" target=\"_blank\"\u003eElimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWen et al., PLoS One 6(1):e15967 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.virol.2010.10.026\" rel=\"noopener\" target=\"_blank\"\u003eChaperonin TRiC\/CCT participates in replication of hepatitis C virus genome via interaction with the viral NS5B protein\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eInoue et al., Virology 410(1):38-47 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.m110.118323\" rel=\"noopener\" target=\"_blank\"\u003eHeat shock protein 72 is associated with the hepatitis C virus replicase complex and enhances viral RNA replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChen et al., J Biol Chem 285(36):28183-28190 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00068-10\" rel=\"noopener\" target=\"_blank\"\u003ePolo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5A\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChen et al., J Virol 84(16):7983-7993 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1000910\" rel=\"noopener\" target=\"_blank\"\u003ePersistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSilberstein et al., PLoS Pathog 6(5):e1000910 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01190-09\" rel=\"noopener\" target=\"_blank\"\u003eIdentification of GBF1 as a cellular factor required for hepatitis C virus RNA replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGoueslain et al., J Virol 84(2):773-787 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4161\/auto.5.7.9243\" rel=\"noopener\" target=\"_blank\"\u003eKnockdown of autophagy-related gene decreases the production of infectious hepatitis C virus particles\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTanida et al., Autophagy 5(7):937-945 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01035-09\" rel=\"noopener\" target=\"_blank\"\u003eCochaperone activity of human butyrate-induced transcript 1 facilitates hepatitis C virus replication through an Hsp90-dependent pathway\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTaguwa et al., J Virol 83(20):10427-10436 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00308-09\" rel=\"noopener\" target=\"_blank\"\u003eNaturally occurring hepatitis C virus subgenomic deletion mutants replicate efficiently in Huh-7 cells and are trans-packaged in vitro to generate infectious defective particles\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePacini et al., J Virol 83(18):9079-9093 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00889-09\" rel=\"noopener\" target=\"_blank\"\u003eHuman VAP-C negatively regulates hepatitis C virus propagation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKukihara et al., J Virol 83(16):7959-7969 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00398-08\" rel=\"noopener\" target=\"_blank\"\u003eAssociation of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLai et al., J Virol 82(17):8838-8848 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1000035\" rel=\"noopener\" target=\"_blank\"\u003eEssential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAppel et al., PLoS Pathog 4(3):e1000035 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.02253-07\" rel=\"noopener\" target=\"_blank\"\u003eA single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOkamoto et al., J Virol 82(7):3480-3489 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.02153-07\" rel=\"noopener\" target=\"_blank\"\u003eHuman butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTaguwa et al., J Virol 82(6):2631-2641 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2353\/ajpath.2007.070413\" rel=\"noopener\" target=\"_blank\"\u003eResponses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTang et al., Am J Pathol 171(6):1831-1846 (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00649-07\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAbe et al., J Virol 81(17):8953-8966 (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.02824-06\" rel=\"noopener\" target=\"_blank\"\u003eMonitoring the antiviral effect of alpha interferon on individual cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKim et al., J Virol 81(16):8814-8820 (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/sj.emboj.7601367\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis C virus RNA replication is regulated by FKBP8 and Hsp90\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOkamoto et al., EMBO J 25(20):5015-5025 (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.75.13.6095-6106.2001\" rel=\"noopener\" target=\"_blank\"\u003eHepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePolyak et al., J Virol 75(13):6095-6106 (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-131_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518875988270,"sku":"HCM-131-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-131-100ug.png?v=1788008520"},{"product_id":"hcm-141","title":"Anti-HCV Helicase. IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 5F6\/H11) obtained by immunization of mice with Helicase antigen (50 kDa) from aa1193 - aa1657 of HCV 1a polyprotein. The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA assays (1:100,000 dilution) and Western Blot analysis (1:16,000 dilution). HCV Helicase is a nucleotide triphosphate - dependent enzyme that catalyzes the unwinding of positive - stranded RNA from hepatitis C virus.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Yao, N. et al (1997) Nat. Struct. Biol. 4, 463 - 467.\u003cbr\u003eGrakoui, A. et al. (1993) J. of Virol. 65, 2832 - 2843.\u003cbr\u003eChoo,Q.-L. et al. (1991) Proc. Natl. Acad. Sci. USA 88, 2451-\u003cbr\u003e2455.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-141_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876021038,"sku":"HCM-141-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-141-100ug.png?v=1788008612"},{"product_id":"hcm-151","title":"Anti-HCV NS3 \/ Helicase. IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 6G12\/C4) obtained by immunization of mice with HCV NS3 \/ Helicase antigen (aa1027 - aa1711 of HCV polyprotein). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA assays (1:8,000 dilution) and Western Blot analysis (1:8,000 dilution). It recognizes specifically NS3 of the NS3 \/ Helicase antigen. HCV NS3 is a serine protease that hydrolyses four peptide bonds in the viral polyprotein yielding the remaining non-structural proteins NS4A, NS4B, NS5A and NS5B.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.5 mg\/mL in PBS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Love, R.A. et al (1996) Cell 87, 331 - 342.\u003cbr\u003eChoo,Q.-L. et al (1991) Proc. Natl. Acad. Sci. USA 88, 2451-2455.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HCM-151_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876053806,"sku":"HCM-151-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hcm-151-100ug.png?v=1788008517"},{"product_id":"hda-230","title":"Hepatitis delta virus antigen p24 (RECOMBINANT)","description":"\u003cp\u003eThe antigen is produced by genetically engineered yeast cells. It covers from Met 1 to Pro 195 of the p24 antigen.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.75 mg\/mL in 0.5M urea, 2M NaCl, 20mM, 1mM EDTA, Tris-HCl (pH 8.0)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1.Structure, sequence and expression of the hepatitis delta viral genome. K.S. Wang et al. Nature 323, 508 (1986).\u003cbr\u003e2. A single anti-genomic reading fram of the hepatitis delta virus encodes the epitopes of both delta antigen polypeptide p24 and p27. A.J. Weiner et al., J. Virol. 62, 594 (1988).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HDA-230_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518876086574,"sku":"HDA-230-3","price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hda-230-10ug.png?v=1788008517"}],"url":"https:\/\/www.australbiologicals.com\/collections\/hepatitis-viruses.oembed","provider":"Austral Biologicals","version":"1.0","type":"link"}